Illumina Stock Shows Recovery Potential Amid Competition. Illumina fundamentals are strengthening with FY26 expected to return to positive growth and enable operating leverage. While competition from Roche and others poses risks, recent market developments appear already priced into the stock, which has stabilized following Roche's Axelios announcement. FY26 guidance projects two percent organic growth with three percent year-over-year EBIT margin expansion, plus additional upside from the Somalogic acquisition. A DCF valuation model supports a buy rating with a $156 target price, implying 22 percent upside potential as margin expansion and NovaSeq X product mix improvements drive shareholder value creation.
Post from MarketNews_en
Log in to interact with content.